Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

420 PROSTVAC in combination with nivolumab enhanced immune cell infiltration in prostate cancer

Autor: Fatima Karzai, Peter A. Pinto, Antonios Papanicolau-Sengos, Amy Hankin, William L. Dahut, James L. Gulley, Michell Manu, Shania Bailey, Nikki Williams, Houssein Abdul Sater, Ravi A. Madan, Wiem Lassoued, Jennifer L. Marte

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundProstate cancer (PC) is the most common non-cutaneous diagnosed cancer among men in USA.1 Although clinical outcomes are favorable for patients with localized disease, 20–30% of patients will develop metastatic prostate cancer (mPC) and h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50de7f06e2f996b849661a64cc757b3
https://doaj.org/article/8e79fc4f580a4855a89071a3c3d4dbd5

Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial

Autor: Ruth MacPherson, Guenter Schmidt, Richard J. Bryant, James W.F. Catto, Armin Meier, Adrian V. S. Hill, L. Carter, Susan Morgan, Megan Baker, Federica Cappuccini, Clare Verrill, Steven Kennish, Selena Vigano, Emily Pollock, Pedro Romero, Julianne Hollidge, Andrew Protheroe, Richard Harrop, Freddie C. Hamdy, Ian D. Poulton, Irina Redchenko, Celia Mitton, Andrea Baines, Tom Evans

Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for a decade. However, neither of the two clinically most developed prostate cancer vaccines, Sipuleucel-T and ProstVac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67eb468d2c3219e40668ef3011daef8b
https://doi.org/10.1101/2020.03.05.20031500

Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure

Autor: Jianbo Li, Nima Sharifi, S. Taylor, Mohammad Alyamani, Ravi A. Madan, Mona Patel, Brian I. Rini, James L. Gulley, M. Berk, Christopher G. Przybycin, Eric A. Klein, Jorge A. Garcia, Edwin M. Posadas, Fumihiko Nakamura

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 31(3)

Background Enzalutamide and apalutamide are potent next-generation androgen receptor (AR) antagonists used in metastatic and non-metastatic prostate cancer. Metabolic, hormonal and immunologic effects of deep AR suppression are unknown. We hypothesiz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91bb7931e3746990abcc0f09fbbfbb26
https://pubmed.ncbi.nlm.nih.gov/32067673

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer

Autor: Fred Saad, James L. Gulley, Chris Parker, Niels C. Langkilde, Frank Priou, Philip W. Kantoff, Andrey Novikov, Per Rathenborg, Liddy M. Chen, Neal D. Shore, Christopher R. Heery, David Pook, Nicholas J. Vogelzang, Siobhan Ng, Joan Carles, Winald R. Gerritsen, Neeraj Agarwal, Thomas W. Flaig, Michael Borre

Publikováno v: Scientia
Gulley, J L, Borre, M, Vogelzang, N J, Ng, S, Agarwal, N, Parker, C C, Pook, D W, Rathenborg, P, Flaig, T W, Carles, J, Saad, F, Shore, N D, Chen, L, Heery, C R, Gerritsen, W R, Priou, F, Langkilde, N C, Novikov, A & Kantoff, P W 2019, ' Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 37, no. 13, pp. 1051-1061 . https://doi.org/10.1200/JCO.18.02031
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Gulley, J L, Borre, M, Vogelzang, N J, Ng, S, Agarwal, N, Parker, C C, Pook, D W, Rathenborg, P, Flaig, T W, Carles, J, Saad, F, Shore, N D, Chen, L, Heery, C R, Gerritsen, W R, Priou, F, Langkilde, N C, Novikov, A & Kantoff, P W 2019, ' Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 37, no. 13, JCO1802031, pp. 1051-1061 . https://doi.org/10.1200/JCO.18.02031
Journal of Clinical Oncology, 37, 13, pp. 1051-1061
Journal of Clinical Oncology, 37, 1051-1061
Recercat. Dipósit de la Recerca de Catalunya
instname
Journal of Clinical Oncology

Càncer de pròstata; Metàstasi neoplàsica; Immunoteràpia Cáncer de próstata; Metástasis neoplásica; Inmunoterapia Prostate cancer; Metastatic neoplasm; Immunotherapy PURPOSE PROSTVAC, a viral vector–based immunotherapy, prolonged median ove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24536971e43858db2d730813a0829a65
https://pubmed.ncbi.nlm.nih.gov/31350066